Magazine Article | January 1, 2017

How Boehringer Ingelheim Is Redefining Its R&D Strategy

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

In November 2015, Boehringer Ingelheim (BI) announced its new five-year R&D strategy, which included a commitment to invest $11 billion. Clive Wood, Ph.D., SVP of discovery research at BI, sat down with Life Science Leader to explain how the company is redefining its R&D strategy in order to maximize internal potential and expand research “for and beyond therapeutic area borders.”

WHY HAS BI DECIDED TO REDEFINE ITS DISCOVERY RESEARCH STRATEGY?
We’ve had a number of strategic initiatives (e.g., Disease Map 2025 looks at aligning diseases, unmet medical need, and scientific opportunities), but I think we’ve gotten to a point where the next step needed to be transformative. In the past, we had a very functionbased organization. And while this was very successful, our goal now is to evolve into an organization that is more customer-centric, which requires being flexible and agile and based around innovation units as well as therapeutic areas. In addition, we realize that many innovations come from the outside world. So in our redefined model, we wanted to communicate better across internal therapeutic areas and have more significant engagement externally.